Below are the most recent publications written about "Boronic Acids" by people in Profiles.
-
Acharya AP, Rafi M, Woods EC, Gardner AB, Murthy N. Metabolic engineering of lactate dehydrogenase rescues mice from acidosis. Sci Rep. 2014; 4:5189.
-
Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, Paul TM, Nichols CW, Porter DL, Kaplan J, Mallon G, Bradner JE, Amaravadi RK. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy. 2014 Aug; 10(8):1380-90.
-
Lu B, Lee J, Nie X, Li M, Morozov YI, Venkatesh S, Bogenhagen DF, Temiakov D, Suzuki CK. Phosphorylation of human TFAM in mitochondria impairs DNA binding and promotes degradation by the AAA+ Lon protease. Mol Cell. 2013 Jan 10; 49(1):121-32.
-
Gibson HM, Mishra A, Chan DV, Hake TS, Porcu P, Wong HK. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome. J Invest Dermatol. 2013 Jan; 133(1):249-57.
-
Gilbert J, Lee JW, Argiris A, Haigentz M, Feldman LE, Jang M, Arun P, Van Waes C, Forastiere AA. Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2013 Jul; 35(7):942-8.
-
Wheatley MA, Cochran MC, Eisenbrey JR, Oum KL. Cellular signal transduction can be induced by TRAIL conjugated to microcapsules. J Biomed Mater Res A. 2012 Oct; 100(10):2602-11.
-
Gaballa MR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, Ghobrial IM, Munshi N, Anderson KC, Richardson PG. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
-
Dasgupta I, Tanifum EA, Srivastava M, Phatak SS, Cavasotto CN, Analoui M, Annapragada A. Non inflammatory boronate based glucose-responsive insulin delivery systems. PLoS One. 2012; 7(1):e29585.
-
Kubicek GJ, Axelrod RS, Machtay M, Ahn PH, Anne PR, Fogh S, Cognetti D, Myers TJ, Curran WJ, Dicker AP. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):1192-7.
-
Sbenghe MM, Besa E, Mahipal A, Dulau Florea A, Bray P, Caro J. HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease. Oncologist. 2012; 17(1):145-6; author reply 147-8.